E
Eyebot
Health Tech & Medtech · Boston, United States · Founded 2021
AI-powered vision tests in 90 seconds, prescription-ready MoreLess
Eyebot is a Boston-based health technology company, founded in 2021 by Matthias Hofmann and Jack Duan, focused on increasing access to vision care. Hofmann, the CEO, has a Ph.D. in Electrical Engineering and a background in building vision and optical startups, including experience at Harvard Medical School and EyeNetra, where he worked on smartphone-based vision exams. This prior experience highlighted the challenges in user adoption and accuracy with mobile-based solutions, leading him to develop Eyebot's proprietary kiosk technology from the ground up.
The company operates on a B2B2C model, addressing a significant market gap caused by a shortage of eye care professionals and the inconvenience of traditional eye exams. Eyebot's core product is a freestanding, self-service kiosk that provides a comprehensive vision test in approximately 90 seconds. These kiosks are strategically placed in high-traffic retail locations like malls, universities, and grocery chains through partnerships with companies such as Zenni Optical and Simon Malls. The vision test is offered to consumers for free, a cost subsidized by the retail partner. The business generates revenue by charging a fee of approximately $20-$30 for a prescription and by leasing the kiosks to its retail partners.
The Eyebot kiosk utilizes a suite of technologies, including a contactless scanner using safe infrared light, to measure visual acuity, refraction, and lensometry (scanning existing glasses). The process is designed to be intuitive, requiring users to simply stand and look at a screen. The collected data is then securely sent to a network of remote, licensed eye doctors who review the results and, if appropriate, issue a verified prescription via email within about 24 hours. The system is built to ensure clinical oversight, flagging any unusual results and referring those patients to in-person care. This approach allows one kiosk to perform over 300 sessions per day, a significant increase compared to a traditional exam lane.
Eyebot has secured significant financial backing to fuel its expansion, including a $6 million seed round in June 2024 and a $20 million Series A round in August 2025, led by General Catalyst. The company is also a participant in the National Science Foundation's I-Corps program. Since its pilot phase, Eyebot has delivered tens of thousands of vision tests and plans to use its funding to deploy hundreds of new kiosks, scale its clinical and engineering teams, and deepen its engagement with eye care professionals. Keywords: vision testing kiosk, automated eye exam, tele-optometry, prescription eyewear, retail health, accessible eye care, health-tech, medical diagnostics, point-of-sale prescriptions, contactless vision test, AI-powered diagnostics, doctor-verified prescriptions, Zenni Optical partner, General Catalyst portfolio, Matthias Hofmann, eye care accessibility, vision screening, digital health, optical retail technology, remote eye doctors, National Science Foundation I-Corps, self-service healthcare, B2B2C health, vision care technology, eye exam automation
Company overview
Eyebot company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2021
- Headquarters
- Boston, United States
- Employees
- 39
- Open positions
- 5
- Dealroom signal
- 91.0
Valuation & funding
Eyebot funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Aug 2025 | $20M | $80M | Village Global · Ravelin Capital · AlleyCorp · Baukunst | ↗ |
| SEED✓Equity / VC | Jun 2024 | $6M | $24M | Spacecadet Ventures · Baukunst · AlleyCorp · Ubiquity Ventures | ↗ |
| GRANTOther financing | Sep 2023 | $1M | — | US National Science Foundation | — |
| SEEDEquity / VC | Oct 2022 | $2.1M | $8.4M | Village Global · Baukunst | — |
| ANGELEquity / VC | Oct 2021 | $530K | $2.1M | US National Science Foundation · Village Global | — |
Financials
Workforce over time
Available workforce history. Financial fields without reported data are omitted.
| Year | Employees |
|---|---|
| 2026 | 39 |
| 2025 | 33 |
| 2024 | 15 |
| 2023 | 9 |
Growth signals
Eyebot website traffic
Latest recorded traffic for Eyebot is 8.1K monthly website visits, down 26.4% over the last three months. Eyebot's team grew 18.2% over the past year.
Hiring
Open positions at Eyebot
Current openings linked to this company in Dealroom.
Comparisons
Eyebot compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Eyebot's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Eyebot has talent and traffic
team presence
In the news
Latest news about Eyebot
Recent press, funding announcements, and product moves mentioning Eyebot — open to read from the original sources.
Market sentiment
What the market is saying about Eyebot
An AI-synthesized read of the highest-engagement posts about Eyebot on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Eyebot’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.
















